We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Constellation Brands
STZ
$22.5B
| $14.4M | 0.02% |
104,057
-472
| -0.5% | -$64.8K |
|
|
HOLX
527
DELISTED
Hologic
HOLX
| $14.3M | 0.02% |
191,867
-2,090
| -1% | -$153K |
|
528
KeyCorp
KEY
$23.8B
| $14.3M | 0.02% |
691,134
-2,635
| -0.4% | -$49.1K |
|
529
Principal Financial Group
PFG
$24.3B
| $14.3M | 0.02% |
161,708
-8,393
| -5% | -$708K |
|
530
Diamondback Energy
FANG
$56B
| $14.2M | 0.02% |
94,685
-2,822
| -3% | -$416K |
|
531
Liberty Media Series C
FWONK
$25.5B
| $14.2M | 0.02% |
144,305
-11,763
| -8% | -$1.15M |
|
532
Carvana
CVNA
$47.5B
| $14.2M | 0.02% |
168,365
+37,135
| +28% | +$2.76M |
|
533
Incyte
INCY
$25.8B
| $14.2M | 0.02% |
143,715
-3,696
| -3% | -$358K |
|
534
Fulcrum Therapeutics
FULC
$241M
| $14.2M | 0.02% |
1,254,027
+1,116,066
| +809% | +$11.4M |
|
535
GE HealthCare
GEHC
$32.5B
| $14.1M | 0.02% |
172,466
-1,862
| -1% | -$145K |
|
536
Roper Technologies
ROP
$40.4B
| $14.1M | 0.02% |
31,686
-309
| -1% | -$143K |
|
537
Snap-on
SNA
$21.5B
| $14M | 0.02% |
40,693
+194
| +0.5% | +$66.3K |
|
538
Kadant
KAI
$3.58B
| $13.9M | 0.02% |
48,881
+702
| +1% | +$199K |
|
|
DEC
539
Diversified Energy Company
DEC
$902M
| $13.9M | 0.02% |
+959,988
| New | +$13.4M |
|
540
Brown & Brown
BRO
$25.1B
| $13.8M | 0.02% |
173,615
-9,949
| -5% | -$830K |
|
541
Global Payments
GPN
$24.1B
| $13.8M | 0.02% |
178,306
-1,509
| -0.8% | -$121K |
|
542
Super Micro Computer
SMCI
$16.6B
| $13.7M | 0.02% |
467,985
-2,971
| -0.6% | -$122K |
|
543
Masco
MAS
$14.3B
| $13.7M | 0.02% |
215,673
-22,168
| -9% | -$1.44M |
|
544
Helios Technologies
HLIO
$2.47B
| $13.7M | 0.02% |
+255,773
| New | +$13.8M |
|
545
DTE Energy
DTE
$29.9B
| $13.6M | 0.02% |
105,436
+11,972
| +13% | +$1.63M |
|
546
Knowles
KN
$2.95B
| $13.6M | 0.02% |
634,355
+267,400
| +73% | +$6.09M |
|
547
Supernus Pharmaceuticals
SUPN
$2.7B
| $13.5M | 0.02% |
+271,574
| New | +$13.2M |
|
548
Rollins
ROL
$18.6B
| $13.5M | 0.02% |
224,252
-33,263
| -13% | -$1.95M |
|
549
Cooper Companies
COO
$14.2B
| $13.4M | 0.02% |
164,041
+13,149
| +9% | +$984K |
|
550
Ameren
AEE
$30.4B
| $13.4M | 0.02% |
134,230
+1,133
| +0.9% | +$116K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.